Background: Accumulating evidence points to an overactive immune response in Covid-19
disease and potential clinical benefit of the interleukin-6 inhibitor tocilizumab. We assessed …

Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment
for hospitalized patients with COVID-19 disease. Methods Open-label randomized phase II …

Importance Pneumonia due to COVID-19 can lead to respiratory failure and death due to the
development of the acute respiratory distress syndrome. Tocilizumab, a monoclonal …

Materials and methods Online databases (PubMed and Cochrane) were searched until
June 29, 2020, for original articles investigating the immunological response in COVID-19 …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Background: Tocilizumab may reduce the risk of death, length of stay, and time of
mechanical ventilation in patients hospitalized with COVID-19. Limited data are available …

Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of tocilizumab for treating patients with …

Background This meta-analysis was conducted to investigate the impact of tocilizumab on
clinical outcomes associated with COVID-19. Methods A comprehensive search was …